Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02895295
Other study ID # IRB-38241
Secondary ID CDR-1306-0359820
Status Completed
Phase N/A
First received
Last updated
Start date September 10, 2016
Est. completion date January 20, 2017

Study information

Verified date July 2019
Source Stanford University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this study is to determine whether providing Medicare beneficiaries with a web-based patient-centered decision tool to help them choose among prescription medication coverage plans improves outcomes for patients including a greater likelihood of changing a plan, better coverage for prescribed drugs, less decisional conflict when choosing plans, and greater satisfaction with the choice process relative to current practice.


Description:

In this study, the investigators tested the effectiveness of two versions of a web-based tool (called CHOICE) to help people choose among Medicare Part D plans (Treatments A and B) relative to standard care (Control). Both treatment arms incorporated simplified design and automated importation of an individual's prescription drugs relative to standard care. The treatment arms varied based on whether they provided expert guidance on recommended plans. In the control arm, study participants were directed to the existing, publicly available Medicare.gov website and received instructions on how to download their drugs from the Palo Alto Medical Foundation (PAMF) patient-facing online personal health portal (myhealthonline). The study sample included PAMF patients who were enrolled in Part D plans (not Medicare Advantage) during the 2016 enrollment period. Prior to the 2017 open enrollment period (October 15 to December 7, 2016), we invited a subset of PAMF patients not covered by either MediCal or a Medicare Advantage plan, aged 66-85, residing in 4 counties served by PAMF, and with at least one active medication order to participate in a study examining the effectiveness of decision tools that provide personalized information on the financial implications of enrolling in different Part D plans. The primary study outcomes included 1) Plan switching, 2) Decisional conflict 3) Satisfaction with the choice process, and 4) Change in generosity of coverage of prescription drugs. The investigators measured the primary study outcomes using a combination of administrative data and a post open enrollment survey. The investigators also collected information on individual characteristics at the time of enrollment in the study and implemented a survey examining use of the intervention tool to assess patient experience at the time of use.


Recruitment information / eligibility

Status Completed
Enrollment 1185
Est. completion date January 20, 2017
Est. primary completion date January 20, 2017
Accepts healthy volunteers No
Gender All
Age group 66 Years to 85 Years
Eligibility Inclusion Criteria:

- The study population included Medicare beneficiaries who received care from the Palo Alto Medical Foundation, a large multi-specialty group in the San Francisco Bay Area ages 66-85, one per household enrolled in a Medicare Part D plan in 2016.

Exclusion Criteria:

- Enrolled in a Medicare Advantage Plan and/or MediCal

Study Design


Related Conditions & MeSH terms

  • Prescription Drug Insurance Decision Making

Intervention

Behavioral:
Expert Recommendation
Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
Individual Analysis
Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
Usual Care
Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.

Locations

Country Name City State
n/a

Sponsors (3)

Lead Sponsor Collaborator
Stanford University Palo Alto Medical Foundation, Patient-Centered Outcomes Research Institute

References & Publications (1)

Linder SK, Swank PR, Vernon SW, Mullen PD, Morgan RO, Volk RJ. Validity of a low literacy version of the Decisional Conflict Scale. Patient Educ Couns. 2011 Dec;85(3):521-4. doi: 10.1016/j.pec.2010.12.012. Epub 2011 Feb 5. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Count of Participants Whose 2017 Plan Differed From Their 2016 Plan Indicator of whether the self-reported plan of the participant differed before and after open enrollment and the participant reported that s/he changed plans during open enrollment. within 50 days of the end of the open enrollment period.
Primary Decisional Conflict Low literacy decisional conflict scale (Linder et al., 2011), edited slightly for context of health insurance rather than treatment choice. The scale has 4 subscales (uncertainty, informed, values clarity and support) with 2 to 3 questions per subscale. Respondents can indicate "yes", "no", or "unsure" for each item. An answer of "yes" receives 0, "unsure" receives 2 and "no" receives 4 points. The sum of the responses to each question within a subscale is normalized to a scale of 25. The subscales are then summed to a total score ranging from 0 to 100 where 0 represents the lowest level of decisional conflict and 100 represents the highest level of decisional conflict. within 50 days of the end of the open enrollment period.
Primary Satisfaction With the Choice Process Response to the question of, "How satisfied are you with the process of choosing a plan?" with 4 potential responses: very satisfied, somewhat satisfied, somewhat dissatisfied and very dissatisfied. The count of participants who responded "very satisfied" is reported. within 50 days of the end of the open enrollment period
Primary Change in Estimated Prescription Drug Spending Change in estimated prescription drug spending is the difference in estimated spending in US dollars, including both premiums and out-of-pocket spending on prescription drugs, between the participant's 2016 and 2017 plans based on their initial drug list. within 50 days of the end of the open enrollment period